Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favo...
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of...
Magnificent Seven, beware. Kai Wu says Wall Street's AI darlings are shifting toward a riskier, capital-heavy model.
- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantl...
Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, toda...
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for...
